 |
|
Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention
Graham C. Wong, MD;
Robert P. Giugliano, MD, SM;
Elliott M. Antman, MD
JAMA. 2003;289:331-342.
Context Low-molecular-weight heparins (LMWHs) possess several potential pharmacological advantages over unfractionated heparin as an antithrombotic agent.
Objective To systematically summarize the clinical data on the efficacy and safety of LMWHs compared with unfractionated heparin across the spectrum of acute coronary syndromes (ACSs), and as an adjunct to percutaneous coronary intervention (PCI).
Data Sources We searched MEDLINE for articles from 1990 to 2002 using the index terms heparin, enoxaparin, dalteparin, nadroparin, tinzaparin, low molecular weight heparin, myocardial infarction, unstable angina, coronary angiography, coronary angioplasty, thrombolytic therapy, reperfusion, and drug therapy, combination. Additional data sources included bibliographies of articles identified on MEDLINE, inquiry of experts and pharmaceutical companies, and data presented at recent national and international cardiology conferences.
Study Selection We selected for review randomized trials comparing LMWHs against either unfractionated heparin or placebo for treatment of ACS, as well as trials and registries examining clinical outcomes, pharmacokinetics, and/or phamacodynamics of LMWHs in the setting of PCI. Of 39 studies identified, 31 fulfilled criteria for analysis.
Data Extraction Data quality was determined by publication in the peer-reviewed literature or presentation at an official cardiology society–sponsored meeting.
Data Synthesis The LMWHs are recommended by the American Heart Association and the American College of Cardiology for treatment of unstable angina/non–ST-elevation myocardial infarction. Clinical trials have demonstrated similar safety with LMWHs compared with unfractionated heparin in the setting of PCI and in conjunction with glycoprotein IIb/IIIa inhibitors. Finally, LMWHs show promise as an antithrombotic agent for the treatment of ST-elevation myocardial infarction.
Conclusions The LMWHs could potentially replace unfractionated heparin as the antithrombotic agent of choice across the spectrum of ACSs. In addition, they show promise as a safe and efficacious antithrombotic agent for PCI. However, further study is warranted to define the benefit of LMWHs in certain high-risk subgroups before their use can be universally recommended.
Author Affiliations: TIMI Study Group, Brigham and Women's Hospital, Boston, Mass.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Goodman et al.
Chest 2008;133:708S-775S.
ABSTRACT
| FULL TEXT
Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes
Eikelboom et al.
Circulation 2006;114:774-782.
ABSTRACT
| FULL TEXT
Angiographic and Clinical Outcomes in Patients Receiving Low-Molecular-Weight Heparin Versus Unfractionated Heparin in ST-Elevation Myocardial Infarction Treated With Fibrinolytics in the CLARITY-TIMI 28 Trial
Sabatine et al.
Circulation 2005;112:3846-3854.
ABSTRACT
| FULL TEXT
Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction: A Meta-Analysis of the Randomized Trials
Eikelboom et al.
Circulation 2005;112:3855-3867.
ABSTRACT
| FULL TEXT
Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events
Collet et al.
Eur Heart J 2005;26:2285-2293.
ABSTRACT
| FULL TEXT
Percutaneous Coronary Intervention and Adjunctive Pharmacotherapy in Women: A Statement for Healthcare Professionals From the American Heart Association
Lansky et al.
Circulation 2005;111:940-953.
ABSTRACT
| FULL TEXT
Effects of Reviparin, a Low-Molecular-Weight Heparin, on Mortality, Reinfarction, and Strokes in Patients With Acute Myocardial Infarction Presenting With ST-Segment Elevation
The CREATE Trial Group Investigators*
JAMA 2005;293:427-435.
ABSTRACT
| FULL TEXT
Managing Complications of Anticoagulant Therapy
Smythe et al.
Journal of Pharmacy Practice 2004;17:327-346.
ABSTRACT
Diminishing returns ...and too many choices ...the saga of pharmacologic therapy to reduce the complications of percutaneous coronary intervention
Stadius
J Am Coll Cardiol 2004;44:25-27.
FULL TEXT
The re-emergence of anticoagulation in coronary disease
Antman
Eur Heart J Suppl 2004;6:B2-B8.
ABSTRACT
| FULL TEXT
ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB
Evid. Based Med. 2003;8:163-163.
FULL TEXT
Application of Current Guidelines to the Management of Unstable Angina and Non-ST-Elevation Myocardial Infarction
Braunwald
Circulation 2003;108:III-28-37.
ABSTRACT
| FULL TEXT
Should Bivalirudin Replace Heparin During Percutaneous Coronary Interventions?
Antman
JAMA 2003;289:903-905.
FULL TEXT
LMWHs May Replace Unfractionated Heparin for Treatment of Acute Coronary Syndromes
JWatch Emergency Med. 2003;2003:5-5.
FULL TEXT
|
